From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
The Future of Precision Oncology
innovation is fueling a new era in oncology—one defined by scalable, precise, and accessible diagnostic and therapeutic tools.
Beyond the Genome: A New Paradigm for Precision Precision oncology is evolving, from a
genomics-centric model into a multidimensional, patient-driven paradigm. A wave of interconnected technologies—including multi-omics, CRISPR diagnostics, artificial intelligence, and decentral- ized testing—is reshaping how cancer is detected, monitored and treated. 3, 4 What began as targeted testing based on single mutations has become a holistic strategy, lever- aging diverse molecular layers—DNA, RNA, proteins, epigenetics, metabolites—to generate more meaningful clinical insights. 5 As a result, diagnostics are becoming more predictive, more inclusive of disease heterogeneity, and more aligned with real-time patient needs.
C ancer remains one of the world’s leading causes of death, claiming nearly 10 million lives annually. 1 Despite major advance- ments in detection and treatment, the disease’s complexity—spanning over 100 types and count- less molecular subtypes 2 —continues to outpace many conventional approaches. Today, we stand at a critical inflection point. The convergence of biotechnology and digital
Latest Technologies Transforming Precision Oncology Artificial Intelligence: Unlocking Multi-Dimensional Insights
analyzing imaging scans, pathology slides, and biomarkers, AI can detect cancerous changes at a stage when they are most treatable. For example, Google’s DeepMind and other similar systems have demonstrated the ability to surpass human radiologists in detecting breast cancer and other malignancies earlier. 6
AI systems now play a pivotal role in iden- tifying cancer earlier and more accurately. They have become essential for interpreting complex diagnostic outputs, from multi- omics to imaging and CRISPR readouts. By
GENengnews.com | 35
Powered by FlippingBook